← Back to Search

Pharmacogenomic-guided Supportive Care

Pharmacogenomic-guided supportive care for Cancer (IMPPACT Trial)

N/A

Waitlist Available

Led By Justin R Arnall, PharmD

Research Sponsored by Justin Arnall

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up from baseline to day +30, day +60 and day +100 in those who enroll to the study

Awards & highlights

IMPPACT Trial Summary

This trial is looking at whether focused palliative care/symptom management, using a person's genetic factors, can improve quality of life for people who have had hematopoietic cell transplantation.

Eligible Conditions

Cancer
Bone Marrow Transplant

IMPPACT Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ from baseline to day +30, day +60 and day +100 in those who enroll to the study

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~from baseline to day +30, day +60 and day +100 in those who enroll to the study

This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline to day +30, day +60 and day +100 in those who enroll to the study for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Frequency of subjects undergoing PGx testing who receive at least one drug/dose selection or modification.

Secondary outcome measures

Determine the type and frequency of actionable genetic polymorphisms observed in the evaluable population and in the subset that received a drug and/or dose selection/modification

Improvements in symptoms from PGx-guided supportive care

Longitudinal symptoms measurements with PGx-guided supportive care

IMPPACT Trial Design

1Treatment groups

Experimental Treatment

Group I: Pharmacogenomic TestingExperimental Treatment1 Intervention

A pharmacogenomic (PGx) panel will be performed to test for genetic variations in genes related to drug response.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Justin ArnallLead Sponsor

Wake Forest University Health SciencesLead Sponsor

1,242 Previous Clinical Trials

1,004,157 Total Patients Enrolled

Justin R Arnall, PharmDPrincipal InvestigatorWake Forest University Health Sciences

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research endeavor currently seeking participants?

"Affirmative. Per the information on clinicaltrials.gov, this trial is actively enrolling patients - with 130 needed from 1 medical centre - and was last updated November 16th 2022, since its posting February 1st 2021."

Answered by AI

How many individuals are being administered treatment through this clinical experiment?

"Indeed, the information on clinicaltrials.gov confirms that this trial is actively recruiting patients since it was first published on February 1st 2021. 130 participants are needed to be recruited from one medical centre and the study has been updated as recently as November 16th 2022."

Answered by AI

Recent research and studies

JamaJournal

Effect of Inpatient Palliative Care on Quality of Life 2 Weeks After Hematopoietic Stem Cell Transplantation

El-Jawahri, Areej, Thomas LeBlanc, Harry VanDusen, Lara Traeger, Joseph A. Greer, William F. Pirl, Vicki A. Jackson, et al.. 2016. “Effect of Inpatient Palliative Care on Quality of Life 2 Weeks After Hematopoietic Stem Cell Transplantation”. Jama. American Medical Association (AMA). doi:10.1001/jama.2016.16786.

The OncologistJournal

Value of Supportive Care Pharmacogenomics in Oncology Practice

Patel, Jai N., Lauren A. Wiebe, Henry M. Dunnenberger, and Howard L. McLeod. 2018. “Value of Supportive Care Pharmacogenomics in Oncology Practice”. The Oncologist. Oxford University Press (OUP). doi:10.1634/theoncologist.2017-0599.

Clinical Pharmacology & TherapeuticsJournal

Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update

Crews, K R, A Gaedigk, H M Dunnenberger, J S Leeder, T E Klein, K E Caudle, C E Haidar, et al.. 2014. “Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update”. Clinical Pharmacology & Therapeutics. Springer Science and Business Media LLC. doi:10.1038/clpt.2013.254.

cyp2d6Journal